Graf Akcie BCRX (Biocryst Pharmaceuticals Inc.). Diskuze k akciím BCRX. Aktuální informace BCRX.

Základní informace o společnosti Biocryst Pharmaceuticals Inc. (Akcie BCRX)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 2.53B
Hodnota podniku (EV) 2.82B
Tržby 79.136M
EBITDA -175.50
Zisk -214.09
Růst v tržbách Q/Q 1,640.13 %
Růst v tržbách Y/Y 60.87 %
P/E (Cena vůči ziskům) N/A
Forward P/E N/A
EV/Sales 35.58
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 31.99
P/FCF N/A
Price/Book -131.44
Účetní hodnota na akcii -0.11
Hotovost na akcii 1.70
FCF vůči ceně -6.74 %
Počet zaměstnanců 246
Tržba na zaměstnance 321.691k
Profit margin -1,026.35 %
Operating margin -222.69 %
Gross margin 90.59 %
EBIT margin -226.39 %
EBITDA margin -221.78 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst 0.00 %
EPS - Očekávaný růst příští rok 15.38 %
Return on assets -79.84 %
Return on equity 513.75 %
ROIC -66.01 %
ROCE -110.81 %
Dluhy/Equity -18.38
Čistý dluh/EBITDA -0.19
Current ratio 2.30
Quick Ratio 2.21
Volatilita 4.14
Beta 1.70
RSI 44.74
Cílová cena analytiků 9
Známka akcie (dle analytiků) 1.40
Insider ownership 0.90 %
Institutional ownership 59.90 %
Počet akcií 178.87M
Procento shortovaných akcií 11.53 %
Short ratio 7.62 %
Dividenda 0.00
Procentuální dividenda 0.00 %
Dividenda/Zisk N/A %
Obchodovaná od 1994
Země United States

Finanční výsledky akcie BCRX

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$48.835$20.653$25.186$26.353$48.257$13.608
Cost Of Goods Sold$3.726-$1.142$2.297$1.368$0.001
Gross Profit$45.109$20.653$24.044$24.056$46.889$13.607
Research And Development Expenses$107.068$84.888$66.962$61.008$72.758$51.796
SG&A Expenses$37.121$29.514$13.933$11.253$13.047$7.461
Other Operating Income Or Expenses$-0.375$-0.471$-0.56$-0.402$-0.528$-0.121
Operating Expenses$148.29$114.873$82.597$74.96$87.701$59.379
Operating Income$-99.455$-94.22$-57.411$-48.607$-39.444$-45.771
Total Non-Operating Income/Expense$-9.442$-7.032$-8.371$-6.537$-3.575$0.582
Pre-Tax Income$-108.897$-101.252$-65.782$-55.144$-43.019$-45.189
Income Taxes------
Income After Taxes$-108.897$-101.252$-65.782$-55.144$-43.019$-45.189
Other Income------
Income From Continuous Operations$-108.897$-101.252$-65.782$-55.144$-43.019$-45.189
Income From Discontinued Operations------
Net Income$-108.897$-101.252$-65.782$-55.144$-43.019$-45.189
EBITDA$-97.336$-92.455$-55.674$-47.043$-38.255$-45.005
EBIT$-99.455$-94.22$-57.411$-48.607$-39.444$-45.771
Basic Shares Outstanding11610384747367
Shares Outstanding11610384747367
Basic EPS$-0.94$-0.98$-0.78$-0.75$-0.59$-0.68
EPS - Earnings Per Share$-0.94$-0.98$-0.78$-0.75$-0.59$-0.68
# 2020 2019 2018 2017 2016 2015
Current Ratio1.77991.64591.67551.23231.02471.5594
Long-term Debt / Capital0.53880.36310.18880.94170.0474-
Debt/Equity Ratio2.2131.25570.653334.04560.63240.3966
Gross Margin92.370210095.465791.283797.165299.9927
Operating Margin-203.6552-456.2049-227.948-184.4458-81.7374-336.3536
EBIT Margin-203.6552-456.2049-227.948-184.4458-81.7374-336.3536
EBITDA Margin-199.3161-447.659-221.0513-178.511-79.2735-330.7245
Pre-Tax Profit Margin-222.9897-490.2532-261.1848-209.2513-89.1456-332.0767
Net Profit Margin-222.9897-490.2532-261.1848-209.2513-89.1456-332.0767
Asset Turnover0.27860.14060.14130.29330.39440.0994
Inventory Turnover Ratio---4.5940.84860.0015
Receiveable Turnover2.20514.81094.11743.00567.72981.4339
Days Sales In Receivables165.522575.870188.6487121.440447.22254.5451
ROE - Return On Equity-284.683-205.6503-78.5297-3494.49-90.1413-59.7462
Return On Tangible Equity-284.6832-205.6505-78.5297-3494.543-90.1412-59.7462
ROA - Return On Assets-62.1267-68.9535-36.9025-61.3755-35.158-33.015
ROI - Return On Investment-131.285-130.9688-63.7003-203.7917-85.868-59.7461
Book Value Per Share0.24830.44730.85120.02140.65061.0511
Operating Cash Flow Per Share0.1222-0.40990.2379-0.54520.3974-0.0968
Free Cash Flow Per Share0.1227-0.40970.3057-0.54640.3287-0.0988

Porovnání s konkurencí: Akcie BCRX

Společnost P/E PEG Růst v tržbách (roční) Růst v EPS Return on equity P/B Profit margin
BCRX N/A N/A 60.87 % 15.38 % 513.75 % -131.44 -1,026.35 %
Akcie CLDX N/A N/A 96.00 % 2.78 % -32.38 % 10.33 -805.88 %
Akcie EBS 9.27 1.81 35.69 % 11.42 % 20.76 % 1.97 19.62 %
Akcie GILD 16.52 0.56 20.13 % -20.85 % 27.79 % 4.70 0.50 %
Akcie GSK 16.47 3.36 N/A % -14.00 % 29.69 % 4.91 16.86 %
Akcie NVAX N/A N/A 2,252.66 % 21.81 % -150.88 % 19.95 -87.94 %
Akcie RGEN 143.16 3.82 68.12 % 60.00 % 6.88 % 9.47 16.36 %
Akcie RGEN 143.16 3.82 68.12 % 60.00 % 6.88 % 9.47 16.36 %
Akcie SRPT N/A 77.40 33.29 % -21.60 % -94.90 % 9.98 -102.60 %

Nedávné obchody insiderů: Akcie BCRX

Jméno Obchod Cena Objem
William P Sheridan
Senior VP - CMO
Option
22 Feb 2021
$4.15 $171,188
Theresa Heggie
Director
Nákup
18 Nov 2019
$1.45 $7,250
Nancy J Hutson
Director
Nákup
18 Nov 2019
$1.45 $14,500
Robert Alexander Ingram
Director
Nákup
18 Nov 2019
$1.45 $29,000
Kenneth B Jr Lee
Director
Nákup
18 Nov 2019
$1.45 $7,250
Megan Sniecinski
Chief Business Officer
Nákup
18 Nov 2019
$1.45 $65,250
Jon P Stonehouse
President and CEO
Nákup
18 Nov 2019
$1.45 $72,500
Anthony Doyle
Chief Financial Officer
Nákup
11 Aug 2020
$4.08 $220,320
Alane P Barnes
Senior VP and Chief Legal Officer
Option
4 Dec 2020
$4.15 $57,025
Alane P Barnes
Senior VP and Chief Legal Officer
Option
11 Dec 2020
$4.15 $57,025
Jon P Stonehouse
President and CEO
Option
15 Dec 2020
$4.15 $557,254
Yarlagadda S Babu
Senior VP - Drug Discovery
Option
19 Feb 2021
$4.15 $207,500

Diskuze k akciím BCRX